Tonix Pharmaceuticals (TNXP) Q3 2026 earnings summary

Executive summary

• TONMYA Q3 net sales were $15.0M, up 37% QoQ; prescriptions rose 28% to 16,375 as payer access and field activity expanded.

• Q3 net product revenue was $17.2M; net loss widened to $53.3M from $32.0M YoY as commercialization and pipeline investment increased.

• Cash and equivalents were $162.8M at September 30; available resources, including $1.5M in subsequent equity proceeds, were expected to fund operations into early Q3 2027.

• Priority programs included TNX-102 SL for MDD, TNX-4800 for Lyme prevention and TNX-1500 for kidney transplant rejection prevention.

Financial highlights

• Q3 net product revenue was $17.2M vs. $3.3M YoY; TONMYA contributed $15.0M, while Zembrace SymTouch and Tosymra contributed $2.2M.

• Q3 operating loss was $55.4M vs. $33.1M; net loss was $53.3M vs. $32.0M.

• Q3 R&D expense rose to $25.8M from $9.3M; SG&A rose to $45.6M from $25.7M, reflecting pipeline and launch-related costs.

• Nine-month revenue was $37.7M vs. $7.7M; net loss was $134.1M vs. $77.1M.

• Nine-month basic and diluted loss per share was $8.24 vs. $10.42; weighted-average shares were 16.3M vs. 7.4M.

Outlook and guidance

• Cash resources plus $1.5M in subsequent ATM proceeds were expected to fund planned operating and capital needs into early Q3 2027, but not 12 months from filing.

• TNX-4800 adaptive Phase 2 field study was targeted to start in Q1 2027, pending final FDA protocol agreement; DSMB review follows the lead-in cohort.

• TNX-1500 MGH investigator-initiated Phase 2 study was expected to start in Q1 2027, enrolling five adult kidney transplant recipients.

• TNX-102 SL HORIZON Phase 2 enrollment for MDD was ongoing; OASIS topline data for ASD/ASR was expected mid-2027.